New medicines containing classic hallucinogenic and entactogenic psychedelic substance
are under development for various psychiatric and neurological disorders. Many of these, …

Brain regions typically contain intermixed subpopulations of neurons with different
connectivity and neurotransmitters. This complicates identification of neuronal phenotypes in …

Introduction 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic
stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is …

Rationale Individuals suffering from alcohol use disorder (AUD) demonstrate difficulty with
decision-making and impulsivity that may be associated with impaired frontal cortical function. …

Introduction There is a resurgence of interest in the therapeutic potential of psychedelic
substances such as 3,4-methylenedioxymethamphetamine (MDMA). Primary findings from our …

Background While there is a growing body of evidence that the delta opioid receptor ( DOR
) modulates ethanol ( E t OH ) consumption, development of DOR ‐based medications is …

Background Levetiracetam (Keppra) is a commonly prescribed anticonvulsant that has
been shown to attenuate alcohol consumption in an open-label study of treatment-seeking, …

The delta opioid receptor (DOR) agonist DPDPE decreases ethanol (EtOH) consumption
when injected into the ventral tegmental area (VTA). We previously showed that DPDPE …

The carotid bodies are sensitive to glucose in vitro and can be stimulated to cause
hyperglycemia in vivo. The aim of this study was to determine if the carotid bodies are involved in …

To test whether hepatic insulin action and the response to an insulin-induced decrement in
blood glucose are enhanced in the immediate postexercise state as they are during exercise, …